share_log

U.S. Capital Wealth Advisors LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

U.S. Capital Wealth Advisors LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

美国资本财富顾问有限责任公司在Vertex制药公司的头寸(纳斯达克代码:VRTX)
Financial News Live ·  2022/11/27 00:21

U.S. Capital Wealth Advisors LLC cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 4.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,738 shares of the pharmaceutical company's stock after selling 669 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Vertex Pharmaceuticals were worth $4,435,000 at the end of the most recent reporting period.

根据美国资本财富顾问公司最近向美国证券交易委员会披露的信息,该公司在第二季度减持了Vertex制药公司的股份(股票代码:VRTX-GET评级)4.1%。该机构投资者在本季度出售了669股后,持有这家制药公司15,738股股票。截至最近一次报告期结束时,美国资本财富顾问公司在Vertex制药公司的持股价值为443.5万美元。

Several other institutional investors have also recently added to or reduced their stakes in the business. Humankind Investments LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.9% during the second quarter. Humankind Investments LLC now owns 1,836 shares of the pharmaceutical company's stock valued at $517,000 after acquiring an additional 35 shares during the last quarter. Procyon Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 2.8% in the 2nd quarter. Procyon Advisors LLC now owns 1,366 shares of the pharmaceutical company's stock worth $385,000 after purchasing an additional 37 shares during the last quarter. Zions Bancorporation N.A. raised its stake in Vertex Pharmaceuticals by 5.2% during the 2nd quarter. Zions Bancorporation N.A. now owns 753 shares of the pharmaceutical company's stock valued at $212,000 after acquiring an additional 37 shares in the last quarter. Nkcfo LLC raised its stake in shares of Vertex Pharmaceuticals by 0.5% in the 2nd quarter. Nkcfo LLC now owns 8,515 shares of the pharmaceutical company's stock worth $2,399,000 after buying an additional 40 shares in the last quarter. Finally, TFC Financial Management raised its stake in shares of Vertex Pharmaceuticals by 58.0% in the 2nd quarter. TFC Financial Management now owns 109 shares of the pharmaceutical company's stock worth $31,000 after buying an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 91.33% of the company's stock.

其他几家机构投资者最近也增持或减持了该公司的股份。人类投资有限责任公司在第二季度将其在Vertex PharmPharmticals的持股增加了1.9%。人类投资有限责任公司现在拥有1,836股这家制药公司的股票,价值517,000美元,在上个季度又购买了35股。Procyon Advisors LLC在第二季度增持了2.8%的Vertex PharmPharmticals股票。Procyon Advisors LLC在上个季度额外购买了37股后,现在拥有这家制药公司1,366股股票,价值385,000美元。Zion Bancorporation N.A.在第二季度将其在Vertex PharmPharmticals的持股增加了5.2%。Zion Bancorporation N.A.在上个季度增持了37股后,现在持有这家制药公司753股股票,价值21.2万美元。Nkcfo LLC在第二季度将其在Vertex PharmPharmticals的股份增加了0.5%。Nkcfo LLC现在拥有这家制药公司8,515股股票,价值239.9万美元,上个季度又购买了40股。最后,TFC理财在第二季度增持了Vertex PharmPharmticals 58.0%的股份。TFC金融管理公司现在持有这家制药公司109股股票,价值3.1万美元,此前在上个季度又购买了40股。对冲基金和其他机构投资者持有该公司91.33%的股票。

Get
到达
Vertex Pharmaceuticals
Vertex制药公司
alerts:
警报:

Insider Activity at Vertex Pharmaceuticals

Vertex制药公司的内部活动

In other Vertex Pharmaceuticals news, EVP Bastiano Sanna sold 1,791 shares of the business's stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $300.31, for a total value of $537,855.21. Following the completion of the sale, the executive vice president now owns 39,192 shares of the company's stock, valued at $11,769,749.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Vertex Pharmaceuticals news, EVP David Altshuler sold 1,303 shares of the business's stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $303.04, for a total value of $394,861.12. Following the completion of the sale, the executive vice president now owns 36,077 shares of the company's stock, valued at $10,932,774.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Bastiano Sanna sold 1,791 shares of the business's stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $300.31, for a total value of $537,855.21. Following the transaction, the executive vice president now directly owns 39,192 shares of the company's stock, valued at approximately $11,769,749.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,715 shares of company stock valued at $1,125,226. Insiders own 0.40% of the company's stock.

在Vertex PharmPharmticals的其他消息中,执行副总裁巴斯蒂亚诺·桑纳在10月18日星期二的交易中出售了1,791股该公司的股票。这只股票的平均售价为300.31美元,总价值为537,855.21美元。出售完成后,执行副总裁总裁现在持有该公司39,192股股票,价值11,769,749.52美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。在Vertex制药的其他消息中,执行副总裁David·奥特舒勒在11月7日星期一的交易中出售了1,303股该业务的股票。这只股票的平均售价为303.04美元,总价值为394,861.12美元。出售完成后,执行副总裁总裁现在持有该公司36,077股股票,价值10,932,774.08美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。此外,执行副总裁巴斯蒂亚诺·桑纳在10月18日星期二的交易中出售了1,791股该公司的股票。这只股票的平均售价为300.31美元,总价值为537,855.21美元。交易完成后,执行副总裁总裁现在直接持有该公司39,192股股票,价值约11,769,749.52美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士出售了3715股公司股票,价值1,125,226美元。内部人士持有该公司0.40%的股份。

Vertex Pharmaceuticals Price Performance

Vertex制药公司的价格表现

VRTX opened at $312.98 on Friday. The stock has a market cap of $80.34 billion, a price-to-earnings ratio of 24.68, a PEG ratio of 1.78 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 1 year low of $182.66 and a 1 year high of $323.61. The company has a current ratio of 4.70, a quick ratio of 4.55 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average price of $300.50 and a 200 day moving average price of $285.69.
VRTX上周五开盘报312.98美元。该股市值为803.4亿美元,市盈率为24.68倍,市盈率为1.78倍,贝塔系数为0.44。Vertex PharmPharmticals Inc.的一年低点为182.66美元,一年高位为323.61美元。该公司的流动比率为4.70,速动比率为4.55,债务权益比率为0.03。该股的50日移动均价为300.50美元,200日移动均价为285.69美元。

Wall Street Analysts Forecast Growth

华尔街分析师预测经济增长

A number of research firms have recently commented on VRTX. HC Wainwright boosted their price objective on Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Friday, August 5th. JPMorgan Chase & Co. boosted their price objective on Vertex Pharmaceuticals from $319.00 to $327.00 and gave the stock an "overweight" rating in a research note on Monday, October 24th. Argus lifted their target price on Vertex Pharmaceuticals from $320.00 to $340.00 and gave the stock a "buy" rating in a report on Thursday, November 17th. Cowen lifted their target price on Vertex Pharmaceuticals from $315.00 to $330.00 in a report on Friday, October 28th. Finally, Royal Bank of Canada lifted their target price on Vertex Pharmaceuticals from $281.00 to $288.00 and gave the stock a "sector perform" rating in a report on Friday, October 28th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $305.33.

一些研究公司最近对VRTX发表了评论。8月5日,在一份周五的研究报告中,HC Wainwright将Vertex PharmPharmticals的目标价从275.00美元上调至300.00美元,并给予该股“买入”评级。摩根大通将Vertex PharmPharmticals的目标股价从319.00美元上调至327.00美元,并在10月24日周一的一份研究报告中给予该股“增持”评级。Argus在11月17日周四的一份报告中将Vertex PharmPharmticals的目标价从320.00美元上调至340.00美元,并给予该股“买入”评级。考恩在10月28日星期五的一份报告中将Vertex PharmPharmticals的目标价从315.00美元上调至330.00美元。最终,加拿大皇家银行在28日(周五)的一份报告中将顶点制药的目标价从281.00美元上调至288.00美元,并给予该股“行业表现”评级。6名投资分析师对该股的评级为持有,11名分析师给出了买入评级,一名分析师对该公司股票发出了强烈的买入评级。根据MarketBeat.com的数据,Vertex PharmPharmticals的共识评级为“中等买入”,平均目标价为305.33美元。

Vertex Pharmaceuticals Company Profile

Vertex制药公司简介

(Get Rating)

(获取评级)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Vertex制药公司是一家生物技术公司,致力于开发治疗囊性纤维化的疗法并将其商业化。该公司销售SYMDEKO/SYMKEVI、Orkambi和Kalydeco,用于治疗囊性纤维化患者,这些患者的囊性纤维化跨膜传导调节基因具有特定突变;TRIKAFTA用于治疗至少有一种F508del突变的6岁或6岁以上的CF患者。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
  • MarketBeat: Week in Review 11/21 – 11/25
  • Is the 60/40 Portfolio Mix Still in Vogue?
  • Microsoft Shares: Is it Time to Back Up the Truck?
  • Three CBD Stocks to Dominate a Budding Industry
  • Institutional Support for Analog Devices Remains High
  • 免费获取StockNews.com关于Vertex PharmPharmticals的研究报告(VRTX)
  • MarketBeat:回顾一周11/21-11/25
  • 60/40的投资组合组合还在《时尚》杂志上流行吗?
  • 微软股票:是时候备份卡车了吗?
  • 三只CBD股票将主宰一个萌芽行业
  • 机构对ADI的支持仍然很高

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating).

想看看还有哪些对冲基金持有VRTX吗?访问HoldingsChannel.com获取Vertex PharmPharmticals Inc.(纳斯达克代码:VRTX-GET Rating)的最新13F备案文件和内幕交易信息。

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接受Vertex制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vertex制药和相关公司的最新新闻和分析师评级的每日简要摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发